Natural Capsules Limited Sets ₹10.01 Crore Promoter Allotment

Natural Capsules Limited is scheduled to consider on November 13, 2026, a ₹10.01 crore preferential allotment of equity shares and convertible warrants to promoter Sunil Laxminarayan Mundra. The proposal covers 1,12,500 equity shares and 4,50,000 fully convertible equity warrants at a revised price of ₹178 each, following shareholder and exchange approvals.

What will Natural Capsules consider at its November 13 board meeting?

Natural Capsules will consider the allotment of 1,12,500 equity shares and 4,50,000 fully convertible equity warrants to Sunil Laxminarayan Mundra, identified by the company as a promoter individual. The board meeting is also scheduled to consider the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.

The proposed allotment is being undertaken under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. The company added the preferential allotment as an agenda item to the meeting initially called for its second-quarter and first-half FY27 results.

The revised issue consists of two parts. The equity-share component involves up to 1,12,500 shares, while the warrant component involves up to 4,50,000 warrants that are fully convertible into equity shares. Both instruments carry an issue price of ₹178 per unit.

What are the revised terms and value of the preferential issue?

The revised preferential issue has an aggregate value of ₹10.01 crore, comprising ₹2.00 crore from equity shares and ₹8.01 crore from convertible warrants. The revised terms replaced the earlier proposal for 1,25,000 shares and 5,00,000 warrants at ₹160 per security, which had been presented for shareholder approval.

At the revised price, the 1,12,500 equity shares represent a value of ₹2,00,25,000. The 4,50,000 fully convertible warrants represent a value of ₹8,01,00,000. Together, these components total ₹10,01,25,000, reported by the company as a ₹10.01 crore fund raise.

How did shareholders and stock exchanges approve the proposal?

Natural Capsules shareholders approved the preferential issue through special resolutions at an Extraordinary General Meeting held on September 9, 2026. The equity-share resolution received 3,090,923 votes in favour and 183 votes against, translating to 99.99408% support.

The resolution for the issue of convertible warrants received 3,090,901 votes in favour and 205 votes against, or 99.99337% support. Total valid votes cast were 3,091,106 for each resolution through remote e-voting. The voting outcome established shareholder consent before the company moved to the allotment stage.

BSE Limited and the National Stock Exchange of India Limited granted in-principle approvals on November 4, 2026. These approvals facilitate the proposed capital raise, while the board's November 13 consideration concerns the allotment specified in the revised issue terms.

Why is Natural Capsules raising capital through a promoter issue?

Natural Capsules has stated that the proceeds from the preferential issue are intended for working capital and capital expansion. The proposed subscriber is a promoter, rather than a broad group of public investors, and the issue combines immediate equity issuance with warrants that can convert into equity shares.

The structure means the equity-share portion is proposed for allotment as shares, whereas the larger warrant portion is proposed as fully convertible instruments. The disclosed materials do not provide a project-wise split of the proposed working-capital and expansion use, beyond those stated objectives.

Natural Capsules is a manufacturer of hard capsule shells in India. The company had earlier evaluated raising funds through equity shares, convertibles or other eligible securities on a preferential basis, subject to regulatory and shareholder approvals. The current issue follows that fund-raising process and its subsequent revision in quantity and price.

What does the allotment process mean for investors and operations?

For investors, the November 13 board agenda is a corporate action that follows approvals already received from shareholders and the exchanges. The key disclosed figures are the ₹178 issue price, the maximum 1,12,500 shares, and the maximum 4,50,000 warrants proposed for the promoter.

The issue is relevant to the company's capital structure because the warrants are convertible into equity shares. However, the supplied disclosures do not state a conversion timeline, the payment terms for warrants, or the post-issue shareholding pattern. Those details cannot be inferred from the stated aggregate fund-raise amount alone.

Operationally, Natural Capsules has linked the proceeds to working capital and capital expansion. The board meeting also includes the review of Q2 and H1 FY27 financial results, which will provide a separate update on financial performance for the period ended September 30, 2026. Earlier reported Q1 FY27 information noted a consolidated loss of ₹5.7 crore alongside 60% year-on-year growth in standalone profit after tax, but the proposed allotment itself is a distinct corporate action.

Conclusion

Natural Capsules has placed a ₹10.01 crore preferential allotment to promoter Sunil Laxminarayan Mundra before its board for consideration on November 13, 2026. The revised issue covers 1,12,500 equity shares and 4,50,000 convertible warrants at ₹178 each, supported by more than 99.99% shareholder approval and in-principle clearance from BSE and NSE.

The next disclosed event is the board meeting on November 13, which is also scheduled to consider the company’s Q2 and H1 FY27 results. Investors will watch for the board’s allotment decision and any further disclosures on the execution of the issue, warrant conversion terms, and use of proceeds for working capital and capital expansion.